Wells Fargo & Company Reiterates “Equal Weight” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “equal weight” rating reiterated by Wells Fargo & Company in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They presently have a $15.00 price target on the biotechnology company’s stock, down from their prior price target of $60.00. Wells Fargo & Company‘s price target suggests a potential upside of 65.93% from the company’s previous close.

Several other equities research analysts also recently issued reports on QURE. Leerink Partners reiterated an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a report on Monday. Wolfe Research initiated coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Mizuho reissued a “neutral” rating and set a $12.00 price target (down from $33.00) on shares of uniQure in a research report on Tuesday. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Finally, Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, uniQure presently has an average rating of “Hold” and a consensus target price of $34.33.

uniQure Stock Performance

Shares of QURE stock opened at $9.04 on Tuesday. The firm’s 50 day moving average price is $22.54 and its 200-day moving average price is $29.57. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.12 and a current ratio of 10.43. uniQure has a one year low of $7.76 and a one year high of $71.50. The firm has a market cap of $565.27 million, a P/E ratio of -2.62 and a beta of 0.73.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. As a group, equities research analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 12,378 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the transaction, the chief executive officer owned 639,076 shares in the company, valued at $15,248,353.36. The trade was a 1.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christian Klemt sold 6,217 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $148,337.62. Following the completion of the sale, the chief financial officer owned 211,513 shares in the company, valued at $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 50,598 shares of company stock worth $1,248,588. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC increased its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Aberdeen Group plc lifted its stake in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp boosted its holdings in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. increased its stake in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in uniQure in the second quarter valued at approximately $29,217,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
• Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
• Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
• Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
• Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
• Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.